| Similar Articles |
|---|
 |
The Motley Fool
October 31, 2011
Travis Hoium |
Integra LifeSciences Shares Dropped: What You Need to Know Shares of medical device maker Integra LifeSciences fell 14% today after the company released earnings and cut its full-year forecast.   |
The Motley Fool
May 1, 2008
Brian Lawler |
Soliris Brightens Alexion's Quarter Alexion Pharmaceuticals' lone drug posts gargantuan growth. |
The Motley Fool
April 27, 2011
Travis Hoium |
Universal Health Services Shares Popped: What You Need to Know Shares of Universal Health Services jumped as much as 14.5% today to reach a new 52-week high after the company announced earnings. |
The Motley Fool
August 17, 2010
Travers & Jayson |
Is Alexion Pharmaceuticals Burning Out? The first step toward finding a promising biotech company is not to figure out whether the science is any good, but to make sure that the company is financially healthy. |
The Motley Fool
February 1, 2008
Brian Lawler |
Alexion Looks for a Bigger Niche Alexion Pharmaceutical announces sales of its rare blood disorder medication should expand in 2008. |
The Motley Fool
December 29, 2011
Brian Orelli |
Too Early for a New Biotech Orphan? Alexion Pharmaceuticals is profitable with a drug on the market. The next logical step in the progression of a biotech is to buy another company to stock the pipeline. |
The Motley Fool
July 19, 2011
Anand Chokkavelu |
7 Biotechs Near 52-Week Lows Here are the largest seven companies in biotech stocks that are within 20% of their 52-week lows. |
The Motley Fool
April 30, 2007
Brian Lawler |
Alexion Heads Overseas Alexion is headed for approval of its lead compound in the European Union. With no other compounds in clinical stage development, an investment in Alexion is all about the market potential for Soliris. |
The Motley Fool
March 1, 2011
Brian D. Pacampara |
Central European Distribution Shares Plunged: What You Need to Know Shares of Central European Distribution dropped as much as 30% in intraday trading Tuesday after the vodka maker's quarterly results and full-year forecast fell well below Wall Street expectations. |
The Motley Fool
August 27, 2010
Travers & Jayson |
The Most Important Thing about Regeneron Pharmaceuticals Stop obsessing about the science. |
The Motley Fool
August 26, 2010
Travers & Jayson |
Will Onyx Pharmaceuticals Burn You? Is Onyx Pharmaceuticals on strong financial footing? |
The Motley Fool
August 18, 2010
Travers & Jayson |
Will Endo Pharmaceuticals Holdings Burn You? Endo Pharmaceuticals Holdings is cash flow-positive, and has been for quite some time. That's investment nirvana for biotech shareholders. |
The Motley Fool
August 24, 2010
Travers & Jayson |
Will Valeant Pharmaceuticals Burn You? How well has Valeant Pharmaceuticals International tapped the capital markets? Here's a visual summary of the past few years |
The Motley Fool
July 22, 2011
Anand Chokkavelu |
9 Small Biotechs Near 52-Week Lows Here are nine companies in this space that are within 20% of their 52-week lows and have market caps between roughly $200 million and $500 million. |
The Motley Fool
August 17, 2010
Travers & Jayson |
How Long Can Amylin Pharmaceuticals Last? You don't need an advanced degree in pharmacology to find biotech companies with a legitimate chance of hitting it big. |
Chemistry World
May 12, 2015
Phillip Broadwith |
Alexion to buy Synageva for rare disease drugs Rare disease drugmaker Alexion has agreed to buy US biotech Synageva for $8.4 billion in a mix of cash and shares. |
The Motley Fool
January 27, 2006
Stephen D. Simpson |
A Real Triumph for Alexion A powerful clinical result brings FDA approval into sight for this biotech company. Investors, enjoy the day -- this is what makes biotech investing fun and exciting. |
The Motley Fool
August 18, 2010
Charly Travers & Seth Jayson |
Will United Therapeutics Burn You? United Therapeutics is cash flow-positive and has mostly been over the past few years. That's investment nirvana for biotech shareholders. This is a rare beast worthy of additional research. |
The Motley Fool
August 17, 2010
Travers & Jayson |
Interested in Cephalon ? Start Here! Every biotech company wants to discover the cure for cancer, Alzheimer's, or Wii knee. Every biotech investor hopes to catch the next Valeant Pharmaceuticals. |
The Motley Fool
August 9, 2011
Brian Orelli |
Give Avanir Some Time It's going to need it. |
Bio-IT World
May 2006
G. Steven Burrill |
Biotech Turns in Mixed Q1 Performance Biotech closed out a rough month of March, but this did not take the shine off the exceptional performance of the mid- and small-cap biotech companies. |
The Motley Fool
August 18, 2010
Travers & Jayson |
Interested in Elan? Start Here! You don't need an advanced degree in pharmacology to find biotech companies with a legitimate chance of hitting it big. |
The Motley Fool
May 10, 2011
Brian Orelli |
Uncontrolled Crying Over AVANIR's Prescription Data? It's been a slow start, but don't write off this company's pseudobulbar drug just yet. |
The Motley Fool
August 18, 2010
Travers & Jayson |
Will Dendreon Burn You? You don't need an advanced degree in pharmacology to find biotech companies with a legitimate chance of hitting it big. Don't start with the science; ignore the sexy story, and look at the cold, hard cash. How does Dendreon stack up? |
The Motley Fool
September 10, 2011
Rex Moore |
Let's See If Alexion's Growth Is for Real Alexion Pharmaceuticals appears to be in good shape in terms of the intangible assets ratio and tangible book value. |
The Motley Fool
August 26, 2010
Travers & Jayson |
Will BioMarin Pharmaceutical Burn You? Is BioMarin Pharmaceutical on strong financial footing? |
The Motley Fool
August 5, 2011
Brian Orelli |
Still Want to Be the Next Dendreon? The biotech market is punished. |
The Motley Fool
July 14, 2005
Stephen D. Simpson |
Dueling Fools: Protein Design Labs Bear Protein Design Labs could be a big winner, or a major loser. The biotech has a strong business, but today's stock price isn't "great." |
The Motley Fool
August 17, 2010
Travers & Jayson |
How Long Can Biovail Last? Stop obsessing about the science. |
The Motley Fool
November 4, 2005
Stephen D. Simpson |
A $99 Biotech Portfolio Can this biotech six-pack pay off for aggressive investors? Acadia Pharmaceuticals... Alexion Pharmaceuticals... Arena Pharmaceuticals... Crucell NV... DOV Pharmaceutical... Millennium Pharmaceuticals... |
The Motley Fool
May 5, 2009
Brian Orelli |
The Wrong Way to Invest in the Right Stocks Persuading you to invest in biotechs should be easy. Persuading you not to use what seems like a less-risky strategy might be harder. Exchange-traded funds just don't work for this industry. |
The Motley Fool
April 4, 2009
Brian Orelli |
The Wrong Way to Invest in the Right Stocks Exchange-traded funds don't work for this industry. |
The Motley Fool
August 18, 2010
Travers & Jayson |
The Most Important Thing About Human Genome Sciences Is Human Genome Sciences on strong financial footing? Take a look. |
The Motley Fool
January 25, 2005
Charly Travers |
Grading Old-School Biotech Be very wary of biotech IPOs from companies lacking drugs. |
Inc.
May 1, 2002
Kenneth Klee |
The Industry You Can't Afford to Miss After more than two decades of hype, hope, disappointment, and progress, the hundreds of mostly small, money-burning companies that make up the biotech industry are experiencing a decisive shift in their relationship with the giant, rich pharmaceutical companies... |
The Motley Fool
January 5, 2012
Brian Orelli |
Are These Biotech Drug Launches Back on Track? With the annual health-care conference starting up next week, Dendreon and InterMune announced preliminary fourth-quarter sales today. |
The Motley Fool
April 29, 2005
Charly Travers |
Value in Drug Stocks? Looking at some big pharma companies and liking what you see? Take a peek at biotech, too. GlaxoSmithKline... Pfizer... Amgen... Genzyme... etc. |
The Motley Fool
December 31, 2007
Brian Lawler |
The Biotech Year in Review Following the biotech sector is never dull, and 2007 was no exception to the rule. Let's take a look at the highlights and lowlights of 2007. |
The Motley Fool
November 16, 2004
Charly Travers |
Finding Biotech's 50-Baggers Finding these superb biotechs isn't a search for a once-in-a-lifetime opportunity. These great investments pop up a lot more frequently than you may think. |
Bio-IT World
November 2005
G. Steven Burrill |
Biotech Posts Strong Third Quarter Despite overall subpar numbers in September, as compared with the previous four months, this was another excellent quarter for biotech... A good quarter for collaborations... IPO windows open slowly... Biotech still attractive for big pharmaceuticals... |
The Motley Fool
August 8, 2008
Selena Maranjian |
Technical Analysis: A Damning Verdict A new study takes a close look at technical analysis and the results are not impressive. |
Bio-IT World
August 2005
G. Steven Burrill |
Biotech Outperforms Market in Q2 Heading into the summer, biotech widely outperformed the Dow and Nasdaq on a year-to-date basis. But the positive performance is attributable to a mere handful of companies driving the market. |
